Antioxidant Therapy in RYR1-Related Congenital Myopathy
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 7 - Any |
| Updated: | 7/8/2018 |
| Start Date: | February 12, 2015 |
| End Date: | May 30, 2018 |
Background:
- Ryanodine receptor type 1-related myopathies (RYR1-RM) are the most common non-dystrophic
muscle diseases that people are born with in the U.S. They affect development, muscles, and
walking. Researchers want to test a new drug to help people with these diseases.
Objectives:
- To see if the drug N-acetylcysteine decreases muscle damage in people with RYR1-RM. To see
if it improves their exercise tolerance.
Eligibility:
- People age 7 and older with a confirmed genetic diagnosis of RYR1 or a clinical diagnosis
of RYR1 and a family member with a confirmed genetic diagnosis.
Design:
- Participants will be screened with a checklist of criteria. Adult participants may have
a muscle biopsy. A needle will remove a tiny piece of muscle in the lower leg.
- Study visits will take several days.
- Visit 1:
- Medical history
- Physical exam
- Blood, urine, and saliva tests
- Questions about symptoms and quality of life
- Heart, lung, and walking tests
- Muscle Oxygenation Capacity Test. A blood pressure cuff around the thigh will be
tightened for up to 10 minutes.
- Biodex testing, stretching the leg against resistance
- Muscle ultrasounds. A probe will be moved over the skin.
- Participants may be photographed or videotaped during procedures.
- They may have a muscle biopsy.
- Six months later, visit 2 will repeat visit 1. Participants will start taking the study
drug dissolved in water or placebo three times a day for 6 months.
- Participants will stay at NIH for 2 days after starting the study drug.
- Participants will be contacted by phone during the study to monitor side effects
- Six months after starting the study drug, study visit 3 will repeat some or all of visit
1.
- Ryanodine receptor type 1-related myopathies (RYR1-RM) are the most common non-dystrophic
muscle diseases that people are born with in the U.S. They affect development, muscles, and
walking. Researchers want to test a new drug to help people with these diseases.
Objectives:
- To see if the drug N-acetylcysteine decreases muscle damage in people with RYR1-RM. To see
if it improves their exercise tolerance.
Eligibility:
- People age 7 and older with a confirmed genetic diagnosis of RYR1 or a clinical diagnosis
of RYR1 and a family member with a confirmed genetic diagnosis.
Design:
- Participants will be screened with a checklist of criteria. Adult participants may have
a muscle biopsy. A needle will remove a tiny piece of muscle in the lower leg.
- Study visits will take several days.
- Visit 1:
- Medical history
- Physical exam
- Blood, urine, and saliva tests
- Questions about symptoms and quality of life
- Heart, lung, and walking tests
- Muscle Oxygenation Capacity Test. A blood pressure cuff around the thigh will be
tightened for up to 10 minutes.
- Biodex testing, stretching the leg against resistance
- Muscle ultrasounds. A probe will be moved over the skin.
- Participants may be photographed or videotaped during procedures.
- They may have a muscle biopsy.
- Six months later, visit 2 will repeat visit 1. Participants will start taking the study
drug dissolved in water or placebo three times a day for 6 months.
- Participants will stay at NIH for 2 days after starting the study drug.
- Participants will be contacted by phone during the study to monitor side effects
- Six months after starting the study drug, study visit 3 will repeat some or all of visit
1.
Although genetic disorders of muscle that present at birth are rare, RYR1-related myopathies
comprise the most common non-dystrophic congenital myopathy in the United States, with a
prevalence of approximately 1/90,000 people (Amburgey et al, 2011). Causative mutations in
the ryanodine receptor gene of skeletal muscle, RYR1, have been found in several myopathy
subtypes, including central core disease and centronuclear myopathy. These mutations result
in defective excitation-contraction coupling and increased mitochondrial oxidative stress.
Most patients present in childhood with delayed motor milestones, extremity muscle weakness,
impaired ambulation, joint contractures, progressive scoliosis, and in some cases eye
movement paralysis, respiratory failure, or susceptibility to malignant hyperthermia, an
allelic condition. Despite these important morbidities and the risk of early mortality, no
treatments exist to date.
RYR1 encodes a homotetrameric transmembrane ion channel, RyR1, which resides on the terminal
sarcoplasmic reticulum in close proximity to the T-tubule. By releasing calcium from the
sarcoplasmic reticulum into the cytosol in response to muscle fiber stimulation by the motor
neuron at the neuromuscular junction, it mediates excitation-contraction coupling and
functions as a regulator of cellular calcium concentrations and redox homeostasis. Dowling et
al. (2012) recently elucidated the latter mechanism in zebrafish and patient myotubes,
showing that RYR1 mutations result in increased oxidative stress and that this is rescued in
both models by treatment with N-acetylcysteine (NAC), a known anti-oxidant. NAC functions as
a precursor of glutathione, an endogenous antioxidant that becomes deficient during oxidative
stress. This was substantiated by a cystic fibrosis clinical trial in which low glutathione
levels in neutrophils undergoing oxidative stress significantly increased with NAC
administration.
Dowling et al. (2012) found significant changes post NAC treatment including increased travel
distance (endurance) in zebrafish and complete protection from cell death induced by
experimentally increasing oxidative stress in myotubes. Thus NAC was a successful treatment
in both ex vivo and in vivo model systems. Based on these results, we plan to perform a
randomized, double-blinded, placebo controlled clinical trial of NAC in a subgroup of
RYR1-related myopathy patients as the first pathophysiologically based treatment for this
devastating disorder.
The objectives of the study are to determine if NAC reduces oxidative stress, fatigability,
and fatigue in a study population of patients with RYR1-RM. The study population includes
both males and females 7 years of age and older. The study design has two phases. The first
6-month phase will be used to validate the selected outcome measures in RYR1 congenital
myopathy. The second 6-month phase is a randomized, double-blinded, placebo controlled drug
intervention trial. The primary outcome measures are blood glutathione for oxidative stress
and six minute walk test for fatigability. Healthy volunteers will be evaluated to determine
normal values of biomarkers, muscle ultrasound, and near infrared spectroscopy in this rare
disease, in order to develop a comparison between healthy and RYR1-RM individuals.
comprise the most common non-dystrophic congenital myopathy in the United States, with a
prevalence of approximately 1/90,000 people (Amburgey et al, 2011). Causative mutations in
the ryanodine receptor gene of skeletal muscle, RYR1, have been found in several myopathy
subtypes, including central core disease and centronuclear myopathy. These mutations result
in defective excitation-contraction coupling and increased mitochondrial oxidative stress.
Most patients present in childhood with delayed motor milestones, extremity muscle weakness,
impaired ambulation, joint contractures, progressive scoliosis, and in some cases eye
movement paralysis, respiratory failure, or susceptibility to malignant hyperthermia, an
allelic condition. Despite these important morbidities and the risk of early mortality, no
treatments exist to date.
RYR1 encodes a homotetrameric transmembrane ion channel, RyR1, which resides on the terminal
sarcoplasmic reticulum in close proximity to the T-tubule. By releasing calcium from the
sarcoplasmic reticulum into the cytosol in response to muscle fiber stimulation by the motor
neuron at the neuromuscular junction, it mediates excitation-contraction coupling and
functions as a regulator of cellular calcium concentrations and redox homeostasis. Dowling et
al. (2012) recently elucidated the latter mechanism in zebrafish and patient myotubes,
showing that RYR1 mutations result in increased oxidative stress and that this is rescued in
both models by treatment with N-acetylcysteine (NAC), a known anti-oxidant. NAC functions as
a precursor of glutathione, an endogenous antioxidant that becomes deficient during oxidative
stress. This was substantiated by a cystic fibrosis clinical trial in which low glutathione
levels in neutrophils undergoing oxidative stress significantly increased with NAC
administration.
Dowling et al. (2012) found significant changes post NAC treatment including increased travel
distance (endurance) in zebrafish and complete protection from cell death induced by
experimentally increasing oxidative stress in myotubes. Thus NAC was a successful treatment
in both ex vivo and in vivo model systems. Based on these results, we plan to perform a
randomized, double-blinded, placebo controlled clinical trial of NAC in a subgroup of
RYR1-related myopathy patients as the first pathophysiologically based treatment for this
devastating disorder.
The objectives of the study are to determine if NAC reduces oxidative stress, fatigability,
and fatigue in a study population of patients with RYR1-RM. The study population includes
both males and females 7 years of age and older. The study design has two phases. The first
6-month phase will be used to validate the selected outcome measures in RYR1 congenital
myopathy. The second 6-month phase is a randomized, double-blinded, placebo controlled drug
intervention trial. The primary outcome measures are blood glutathione for oxidative stress
and six minute walk test for fatigability. Healthy volunteers will be evaluated to determine
normal values of biomarkers, muscle ultrasound, and near infrared spectroscopy in this rare
disease, in order to develop a comparison between healthy and RYR1-RM individuals.
- EXCLUSION CRITERIA - PATIENTS:
- Adults who cannot provide their own consent and pediatric participants who do not have
a parent able to provide consent.
- Patients with a history of liver disease (Liver Function Tests will be collected at
baseline and
at each study visit as a precautionary measure). Liver disease is defined as moderate to
severe hepatic impairment based on the following:
- ALT greater than or equal to 8x upper limit of normal (ULN) with total bilirubin 2x
ULN (plus >35% direct bilirubin) and/or INR >1.5 or
- GGT > 2-3x ULN with bilirubin 2x ULN (plus >35% direct bilirubin) and/or INR
- Patients with a history of peptic ulcers, gag reflex depression, and esophageal
varices. Patients with gastrostomy tubes may be considered for participation, in
the case of gag reflex depression or other swallowing or feeding difficulties.
- Patients who have a severe pulmonary dysfunction (FEV1< 40% predicted) or
evidence of pulmonary exacerbation. Pulmonary exacerbations refer to an acute
worsening of respiratory symptoms that result from a decline in lung function.
Participants may present with increased coughing, increased dyspnea, increased
haemoptysis, increased fatigue, decreased pulmonary function by a min of 10%, or
a change in sputum color.
- Pregnant and breastfeeding women.
- Consumption of antioxidants [including NAC, GSH, melatonin, Immunocal (Immunotac
Research, Vandreuil-Dorion, QC, Canada), Nacystelyn (Galephar, Brussels)] in the 4 weeks
before recruitment.
-Daily use of acetaminophen (including Percocet, Vicodin, Oxycodone, Excedrin, and other
acetaminophen-containing drugs), nitroglycerine, or carbamazepine during the past 7 days.
- Current use of Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin Receptor
Blockers (ARBs).
- Patients who have ever used Beta2-adrenergic agonist tablets, for the purpose of
increasing muscle mass (such as albuterol tablets).
- For the muscle biopsy procedure only (second and third visits, if applicable):
Patients who have taken Aspirin, Ibuprofen, Advil, Motrin, or Aleve within the 3 days
prior to the muscle biopsy procedure, and/or patients who have taken Plavix, fresh
garlic, gingko, or ginseng 5 days prior to the muscle biopsy.
- Participation in trials for other therapeutic investigational drugs simultaneously or
4 weeks before recruitment.
- Other clinically significant medical disease that, in the judgment of the
investigators, would expose the patient to undue risk of harm or prevent the patient
from completing the study. Examples include anemia (defined as Hgb < 8 gm/dl), an
inability to walk safely without assistance for at least 6 minutes, and/or an
inability to consume at least 6 ounces of fluid, 3 times a day, either orally or via
G-tube. Patients with comorbidities (i.e. cancer, epilepsy) will be carefully assessed
to determine if their comorbidity could lead to confounding or safety issues, should
their participation continue.
EXCLUSION CRITERIA - HEALTHY VOLUNTEERS:
- Diagnosis of RYR1-related myopathy or other neurological disorder (by neurological
exam, genetic testing, or muscle biopsy
- Complaints of fatigue or weakness
- Consumption of antioxidants [including NAC, GSH, melatonin, Immunocal (Immunotac
- Research, Vandreuil-Dorion, QC, Canada), Nacystelyn (Galephar, Brussels)] in the 4
weeks before recruitment.
- Use of Beta2-adrenergic agonists.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
